Drug Discovery

#AI / data analytics / healthtech / informatics #Cell culture #Drug development

Ground-breaking techniques using AI predict cell growth

Ground-breaking research at Teesside University using artificial intelligence to predict the growth rate of living organisms could have far-reaching consequences in the field of pharmaceuticals and medical diagnostics. A team of researchers led by Dr Claudio Angione from the University’s School of Computing, Engineering and Digital Technology looked at how… Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery

Project produces next-generation AI drug discovery platform

The consortium behind the DeepADMET project set up to advance artificial intelligence (AI) technologies for drug discovery, has announced the successful conclusion of this project which was funded by Innovate UK, the UK’s innovation agency. Optibrium – a developer of software for drug discovery, Intellegens – an AI company, and… Read More

#News

#Assay development & optimisation #Drug discovery

Industry insight on designing assays that deliver hits with higher physiological relevance

DDW is delighted to announce an exclusive event, supported by SPT Labtech, that will allow you to gain knowledge on kinetic assay design and take this forward to produce assays that deliver hits with higher physiological relevance. Pharmacology expert Dr Nick Holliday, chief scientific officer, Excellerate Bioscience, will lead this… Read More

#Editor's Choice #News

#Covid-19 #Drug discovery #Therapeutics

New flu therapy may help against COVID-19

A new therapy for influenza virus infections that may also prove effective against many other pathogenic virus infections, including HIV and COVID-19, has been developed by Purdue University scientists. In an average year, more than 2 million people in the United States are hospitalised with the flu, and 30,000 to… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Drug discovery

Biosero and TetraScience R&D data update accelerates drug discovery

Biosero and TetraScience have revealed that they will integrate data glyphs, instruments and robotic sensors with the cloud-native Tetra Data Platform using Green Button Go Automation Scheduling Software. Together the systems will automatically collect, store and harmonize life science R&D data in the cloud to accelerate drug discovery and research. Read More

#News

#Biotechnology #Drug development #Drug discovery #Life sciences #Narrated podcasts #Pharmaceutical #Research

Evolution of User Experience for life sciences

Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design process that centres on the behaviours and needs of users. The clear benefits of UX offered in the retail and consumer sectors have been slow to… Read More

#Podcasts

#Assay development & optimisation #Drug discovery

Pharmacology expert explains how to improve the drug discovery process

In an exclusive event for DDW, Dr Holliday, Chief Scientific Officer, Excellerate Bioscience, will focus on the importance of kinetic assays in drug discovery. What you will learn: How association and dissociation rate constants describe compound binding kinetics The potential clinical benefits of optimising kinetic constants when compound profiling The… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Oncology #Therapeutics

Lantern Pharma AI milestone will cut cost, time and risk in developing new drug therapies

Lantern Pharma has reached a significant milestone by surpassing one billion curated data points on its RADR platform, a total it believes is the most amassed by any company in the biotech sector. The milestone, which was reached well ahead of schedule, enables new opportunities in Lantern’s work to identify and… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trials #Drug development #Therapeutics

First patient recruited for novel precision medicine trial for patients with hypertension

Closed Loop Medicine (CLM) a clinical stage therapeutics company developing drug and digital combination products, has recruited the first patient into its pivotal clinical trial investigating CLM’s integrated precision care solution for patients with hypertension. The clinical trial, called Personal COVID BP, will see up to 1,000 patients recruited for… Read More

#News

#Assay development optimisation & technology #Drug discovery

Why kinetic assays are important to drug discovery

In this free webinar, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience will provide exclusive insight into the importance of kinetic assays in the drug discovery process. Viewers will gain knowledge on kinetic assay design and how to design assays that deliver hits with higher physiological relevance. Putting the dynamics… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Covid-19 #Drug development

Is virtual reality the new tool for COVID-19 drug design?

Bristol scientists have demonstrated a new virtual reality [VR] technique which should help in developing drugs against the SARS-CoV-2 virus – and enable researchers to share models and collaborate in new ways. The innovative tool, created by University of Bristol researchers, and published in the Journal of Chemical Information and… Read More

#Covid-19 #Editor's Choice #News

#Biotechnology #Drug development #Drug discovery #Ingredients / APIs / Fine chemicals #Pharmacokinetics / Pharmacodynamics

Evotec expands UK site into drug discovery & development centre

Evotec is expanding its campus in Abingdon, Oxfordshire, UK, into a major, fully-integrated, co-located discovery and development centre to be named Dorothy Crowfoot Hodgkin Campus. Adding a new building, which will house up to 100 biologists by the end of the year, will bring together all the key functions for… Read More

#News

#Biotechnology #Drug development #Drug discovery #Narrated podcasts #Pharmaceutical

Evolving Models for NASH Drug Discovery: Tools for stemming a silent epidemic

Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this prevalence is allowed to continue the economic and clinical burden will reach a staggering level. Non-alcoholic fatty liver disease (NAFLD) consists of a complex combination of… Read More

#Podcasts